Article open access publication

721PD FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of Oncology, Elsevier, ISSN 1569-8041

Volume 27, 2016

DOI:10.1093/annonc/mdw372.05, Dimensions: pub.1083559159,



  1. (1) Medical Oncology Service, Hopital European George Pompidou, Paris, France
  2. (2) Tulane University, grid.265219.b
  3. (3) Copenhagen University Hospital, grid.4973.9, Capital Region
  4. (4) Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  5. (5) University of Montreal, grid.14848.31
  6. (6) Odense University Hospital, grid.7143.1, Southern Denmark Region
  7. (7) Oncology, Karolinska University Hospital-Radiumhemmet, Stockholm, Sweden
  8. (8) Gdańsk Medical University, grid.11451.30
  9. (9) Medical Oncology, CHU Minjoz Besançon, Besançon, France
  10. (10) Medical Oncology, Ospedale Sta Chiara, Trento, Italy
  11. (11) Hospital Universitario 12 De Octubre, grid.144756.5
  12. (12) Medical Oncology, ICON Cancer Care, Brisbane, Australia
  13. (13) RAND Corporation, grid.34474.30
  14. (14) Research and Development, Sanofi Genzyme, Vitry-sur-Seine, France
  15. (15) Institut Gustave Roussy, grid.14925.3b

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

Dimensions Citation Indicators

Times Cited: 0

Field Citation Ratio (FCR): 0

Open Access Info